November 14, 2016
(Quartz) – Precision medicine—the practice of scanning patients’ genes to devise tailor-made treatment programs—is already routine in rich countries for some diseases. Oncologists in the US and Europe use genetic tests to determine which treatments will work best for their patients’ cancers. But Africans and people of African descent, such as African Americans, have been left behind in this medical revolution. Out of the more than 35 million participants that have participated in genetic screening studies to date, 81% were of European ancestry. Of the rest, three-quarters were Asians. Only 3% were of African origin.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.